DelveInsight’s Diabetic Retinopathy Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Diabetic Retinopathy pipeline domain.
Some of the essential takeaways from the Diabetic Retinopathy Pipeline report:
Request a sample and discover more about the report offerings @ Diabetic Retinopathy Emerging Therapies
The Diabetic Retinopathy pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Diabetic Retinopathy products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Diabetic Retinopathy pipeline landscape.
Diabetic Retinopathy Overview
Diabetic Retinopathy is a serious sight-threatening complication of Diabetes. Diabetes interferes with the body’s ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Diabetic Retinopathy Symptoms include spots or dark strings floating in your vision (floaters), blurred and fluctuating vision, dark or empty areas in your vision as well as vision loss. There are 4 Diabetic Retinopathy Stages including Mild Non Proliferative Diabetic Retinopathy, Moderate Non Proliferative Diabetic Retinopathy, Severe Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy. Diabetic Retinopathy risk factors include independent aspects such as hypertension, duration of diabetes, diabetic neuropathy, diabetic nephropathy, diabetic foot ulcer, foot amputation, fasting blood glucose, serum total cholesterol, serum triglyceride, and HbA1c. Retinal photography and digital imaging are considered to be effective technique for Diabetic Retinopathy screening. Over time, Diabetes damages small blood vessels throughout the body, including the retina. Diabetic Retinopathy occurs when these tiny blood vessels leak blood and other fluids. Diabetic Retinopathy causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic Retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop Diabetic Retinopathy. If left untreated, Diabetic Retinopathy can even cause blindness.
For further information on the Diabetic Retinopathy current pipeline therapeutics, reach out @ Diabetic Retinopathy Ongoing Clinical Trials
Diabetic Retinopathy Pipeline Drugs
Drug
Company
Phase
MoA
RoA
KSI-301
Kodiak Sciences
Phase III
Vascular endothelial growth factors inhibitor
Intravitreal
Brolucizumab
Novartis
Vascular endothelial growth factor A inhibitor
Runcaciguat
Bayer
Phase II
Guanylate cyclase stimulant
Oral
RC 28 E
RemeGen
RG7774
Hoffman-La-Roche
Cannabinoid receptor CB2 agonist
RGX-314
Regenxbio Inc.
Suprachoroidal Delivery
APX3330
Apexian Pharmaceuticals, Inc.
DNA apurinic apyrimidinic site lyase inhibitor
ADVM-022
Adverum Biotechnologies
THR-687
Oxurion
Integrin inhibitor
OCX 063
OccuRx
Preclinical
Angiogenesis inhibitor
NA
BI 764524
Boehringer Ingelheim
Phase I/II
MS-553
MingSight Pharmaceuticals
Phase I
Protein kinase C beta inhibitor
APX-1004
AptaBio Therapeutics
NADPH oxidase inhibitor
EG-Mirotin
EyeGene
Platelet derived growth factor stimulant
Intramuscular
AT 003
Applied Therapeutics
Aldehyde reductase inhibitor
GLY-230
Glycadia
Glycosylation inhibitor
Learn more about the novel and emerging Proliferative Diabetic Retinopathy as well as Non Proliferative Diabetic Retinopathy drugs @ Diabetic Retinopathy Pipeline Analysis
Diabetic Retinopathy Therapeutics Assessment
The Diabetic Retinopathy Pipeline report proffers an integral view of the Diabetic Retinopathy emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Diabetic Retinopathy Pipeline Report
Dive deep into rich insights for emerging therapies and assessment, visit @ Diabetic Retinopathy Pipeline Drugs
Table of Contents
1
Introduction
2
Executive Summary
3
Diabetic Retinopathy: Overview
4
Pipeline Therapeutics
5
Late Stage Products (Phase III)
5.1
KSI-301: Kodiak Sciences
6
Mid Stage Products (Phase II)
6.1
RC28-E: RemeGen
7
Early Stage Products (Phase I/II)
7.1
BI 764524: Boehringer Ingelheim
8
Therapeutic Assessment
9
Inactive Products
10
Collaborations Assessment- Licensing / Partnering / Funding
11
Diabetic Retinopathy- Unmet Needs
12
Diabetic Retinopathy- Market Drivers and Barriers
13
Appendix
14
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight